WaveMan
WaveMan · Company
CRBP · Corbus Pharmaceuticals Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CRBP Corbus Pharmaceuticals (CRBP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001595097
Quote by TradingView
C-suite buying · 1Form 144 · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
55
13F, latest reported quarter

What the filings say about CRBP

Insiders, 180 days
-$254.9K net sold
1 buyer · 6 sellers · 17% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$292.4K
2 notices

Corbus Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Corbus Pharmaceuticals Holdings, Inc. insiders sold a net $254.9K of stock across 76 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Ben Yong
Director
SELL
2026-09-15 SECtraded 2026-09-14
2,000
$15.7K
-45.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 21.3% of the 9,383 shares held after it.
  • No other insider sold within 30 days.
  • 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ben Yong sold about $15.7K of CRBP under a 10b5-1 plan on Sep 14, 2026; 55 funds added in the latest 13F quarter.
Saxena Nishant C
Chief Business Officer
BUY
2026-08-12 SECtraded 2026-08-11
2,600
$25.0K
-60.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 3, 2026.
  • +48.8% median (+48.8% mean) 90-day return after 2 previous buys.
  • The trade is 3.3% of the 77,900 shares held after it.
  • No other insider bought within 30 days.
  • 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Saxena Nishant C bought about $25.0K of CRBP on Aug 11, 2026; 55 funds added in the latest 13F quarter.
Moran Sean F.
Chief Financial Officer
SELL
2026-08-10 SECtraded 2026-08-07
12,000
$121.0K
-58.0%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (3 buys, 7 sales), the last on Feb 13, 2026.
  • -22.9% median (-28.8% mean) 90-day return after 3 previous buys.
  • The trade is 14.2% of the 84,694 shares held after it.
  • 1 other insider sold within 30 days.
  • 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Moran Sean F. sold about $121.0K of CRBP on Aug 7, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.
Cohen Yuval
Chief Executive Officer
SELL
2026-08-10 SECtraded 2026-08-07
17,000
$171.4K
-58.0%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (3 buys, 12 sales), the last on Feb 13, 2026.
  • -23.4% median (-29.0% mean) 90-day return after 3 previous buys.
  • The trade is 10.8% of the 157,316 shares held after it.
  • 1 other insider sold within 30 days.
  • 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Cohen Yuval sold about $171.4K of CRBP on Aug 7, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.
Kung Winston
Director
SELL
2026-06-11 SECtraded 2026-06-10
2,026
$16.0K
-51.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 16.7% of the 12,140 shares held after it.
  • 2 other insiders sold within 30 days.
  • 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kung Winston sold about $16.0K of CRBP on Jun 10, 2026; 2 other insiders sold within 30 days and 55 funds added in the latest 13F quarter.
76 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 71 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$254.9K over 180 days
-$283.0K over 90 days
more than 51% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
55 funds bought in last quarter
below 51% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
23.1% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
more than 87% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CRBP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-77.0%12M
-77%-51%-26%+0%2025-102025-122026-022026-042026-062026-082026-10 2025-12-11 · Chen Bihua sold $344.1K2025-10-24 · Cohen Yuval sold $317.4K2025-10-24 · Moran Sean F. sold $220.9K2026-08-07 · Cohen Yuval sold $171.4K2025-10-27 · Cohen Yuval sold $153.8K2026-08-07 · Moran Sean F. sold $121.0K2026-02-13 · Cohen Yuval sold $107.9K2026-06-03 · Saxena Nishant C bought $68.2K2026-03-02 · Smethurst Dominic sold $50.6K2026-06-10 · Jenkins John Kenneth sold $38.0K2026-02-13 · Moran Sean F. sold $36.6K2026-06-02 · Saxena Nishant C bought $33.0K2026-02-03 · Smethurst Dominic sold $26.6K2026-08-11 · Saxena Nishant C bought $25.0K2026-02-03 · Hodgson Ian sold $19.5K2026-06-10 · Altmeyer Anne sold $19.1K2026-06-10 · Kung Winston sold $16.0K2026-09-14 · Ben Yong sold $15.7K2026-02-17 · Hodgson Ian sold $6.3K2026-08-07 · Stifel, Nicolaus & Company, Inc CIAS /FA filed to sell $171.4K2026-08-07 · Stifel, Nicolaus & Company, Inc CIAS /FA filed to sell $121.0K2026-07-27 · Smethurst Dominic filed to sell $211.8K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CRBP: institutional holders (13F)

13F holdings, latest reported quarter
Cormorant Asset Management, LP
2,344,971 sh
$22.0M
ORBIMED ADVISORS LLC
1,737,287 sh
$16.3M
BlackRock, Inc.
1,331,135 sh
$12.5M
Aberdeen Group plc
1,321,750 sh
$12.4M
Stonepine Capital Management, LLC
850,000 sh
$8.0M

Congress trades in CRBP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CRBP planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Stifel, Nicolaus & Company, Inc CIAS /FA
Filed 2026-08-07
$171.4K
Stifel, Nicolaus & Company, Inc CIAS /FA
Filed 2026-08-07
$121.0K
Smethurst Dominic
Filed 2026-07-27
$211.8K

CRBP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$519.2K position · as of 2026-06-30
0.0%
BlackRock Advantage SMID Cap V.I. Fund
$28.7K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$35.1K position · as of 2026-06-30
0.0%
VIP Disciplined Small Cap Portfolio
$73.0K position · as of 2026-06-30
0.0%
iShares Russell 2000 Value ETF
$1.5M position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$215.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.8M
$2.6M
$1.8M
+144%
n/a
2024
$4.2M
$4.1M
$2.7M
+254%
n/a
2023
$1.1M
$1.4M
$778.6K
+81%
n/a
2022
$1.4M
$406.6K
$771.2K
-91%
n/a
2021
$4.9M
$1.4M
$930.4K
-51%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $254.9K sold by insiders over 180 days, 55 funds added last quarter, $292.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CRBP financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.12x
long-term 2024-03-31 (27 months older than the period end) plus current 2024-03-31 (27 months older than the period end); equity 2026-06-30
Cash flow to debt
-6.79x
TTM operating cash flow over long-term 2024-03-31 (27 months older than the period end) plus current 2024-03-31 (27 months older than the period end)
Return on equity
-95.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-80.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-98.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$66.6M
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term 2024-03-31 (27 months older than the period end) plus current 2024-03-31 (27 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/an/a$0
Operating income-$85.3M-$48.7M-$45.1M-$39.8M
Net income-$78.5M-$40.2M-$44.6M-$42.3M
EPS (diluted)-5.90-3.68-10.31-10.15
Operating cash flow-$64.5M-$41.8M-$36.1M-$37.5M
Cash$28.5M$17.2M$13.7M$17.0M
Long-term debtn/an/a$0$16.0M
SEC XBRL, fiscal years, as known on 2026-10-28

CRBP Stock Sonar score 6/7 axes

Find similar shapesCompare

CRBP ranks highest on insider conviction (52nd percentile) and risk and compliance (51st), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
30
Inputs
  • Return on equity-95.6% · 35 pct, sector of 545
  • Return on assets-80.9% · 29 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-98.4% · 26 pct, sector of 576
Financial health
39
Inputs
  • Debt to equity0.12x · 51 pct, sector of 352
  • Cash flow to debt-6.79x · 26 pct, sector of 371
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
52
Inputs
  • Net Form 4 buying (codes P and S), 180d-$239K · 49 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
49
Inputs
  • Funds adding, latest quarter55 · 49 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
51
Inputs
  • Short interest, % of float+23.1% · 10 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.1% · 92 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CRBP filings, in plain words

Are Corbus Pharmaceuticals insiders buying or selling CRBP?

In the 180 days to 2026-10-28, Corbus Pharmaceuticals insiders were net sellers, a net $254.9K: $126.2K of purchases and $381.1K of sales reported on Form 4, by 1 buyer and 6 sellers.

Are there planned insider sales of CRBP?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $292.4K of stock; the latest, by Stifel, Nicolaus & Company, Inc CIAS /FA, was filed 2026-08-07.

Read the full summary

In the 180 days to 2026-10-28, Corbus Pharmaceuticals insiders were net sellers of CRBP, a net $254.9K across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. 17% of the 6 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $292.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies